Cover Image
市場調查報告書

美國的腫瘤學路徑:製藥公司敵人還是夥伴

Oncology Pathways in the US - Friend or Foe for Pharma?

出版商 Datamonitor Healthcare 商品編碼 342056
出版日期 內容資訊 英文 59 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的腫瘤學路徑:製藥公司敵人還是夥伴 Oncology Pathways in the US - Friend or Foe for Pharma?
出版日期: 2015年07月31日 內容資訊: 英文 59 Pages
簡介

美國的癌症治療成本正在急速上升。支付治療費用的人關注於臨床路徑的使用。

本報告提供臨床路徑使用之相關資料檢驗,以其價值及品質為焦點,提供您有系統之資訊。

摘要整理

腫瘤學費用的經營管理

  • 腫瘤學支出的增加
  • 所謂臨床路徑
  • 參考文獻

腫瘤學臨床路徑的計劃與開發業者

  • 腫瘤學路徑的開發業者
  • 路徑的設計和結構
  • 參考文獻

路徑對腫瘤學的影響

  • 少數美國付款者引進腫瘤學路徑
  • 路徑腫瘤學治療標準化,有可能降低成本
  • 腫瘤學路徑的使用的推動因素·阻礙因素
  • 腫瘤學的付款形勢的變化上路徑的立場
  • 參考文獻

與腫瘤學路徑製藥公司

  • 路徑在最初階段,臨床開發計劃
  • 腫瘤學路徑,仰賴可利用的生物標記
  • 跟第三方路徑供應商對話的透明度
  • 腫瘤學路徑,具有保護新高額治療的可能性
  • 參考文獻

腫瘤學路徑的未來

  • 片斷化或整合
  • 擴大患者有限的作用
  • 腫瘤學醫療社會促進路徑
  • 醫療的「巨量資料」
  • 參考文獻

圖表

目錄
Product Code: DMKC0142369

The costs of treating cancer in the US are spiraling upward, and payers have taken notice. The growing focus on value and quality has driven greater use of clinical pathways: structured, standardized, evidence-based patient management plans that typically favor the most effective, least toxic, and lowest cost treatment options. Providers implement pathways to align treatment with best practices, and payers have used pathways in several models that tie incentives to oncologists' adherence to on-pathway treatment.

Results from recent research with US payers suggest that the trend is toward a growing market for pathways, with a significant proportion of payers expecting the use of oncology pathway programs to increase. Given the potential of clinical pathways to open up markets to oncology medicines - or to erect significant barriers to their use - the pharmaceutical industry needs to carve out a more substantial role in the development or implementation of pathway-based payment programs, while bearing in mind that pathways are only one of the many tools that payers are using as they shift from paying for volume to reimbursing value.

This report addresses the following questions:

  • Who is developing and using oncology clinical pathways?
  • What is the role of oncology pathways in the evolving oncology cost management strategies?
  • What impact have oncology pathways had on the oncology drug use so far?
  • What are the drivers and resistors of wider use of oncology pathways from the perspective of different stakeholders?
  • What key developments in the US reimbursement landscape are likely to influence the use of oncology pathways in the future and what will their impact will be?
  • What strategies do pharmaceutical companies need to implement to mitigate the potential negative impact of oncology pathways on their oncology products or maximize opportunities?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • 1. The growing need for better management of oncology costs
  • 2. Overview of oncology clinical pathway programs
  • 3. The impact of pathways on oncology
  • 4. Oncology pathways and pharma
  • 5. Future of oncology pathways

MANAGEMENT OF ONCOLOGY COSTS

  • 6. As oncology spending grows, so does payers' use of utilization controls
  • 7. Clinical pathways - what, who, and where?
  • 8. Bibliography

ONCOLOGY CLINICAL PATHWAY PROGRAMS AND DEVELOPERS

  • 9. Oncology pathway developers
  • 10. Design and structure of pathways
  • 11. Bibliography

THE IMPACT OF PATHWAYS ON ONCOLOGY

  • 12. A minority of US payers have implemented oncology pathways, but many expect use to
  • Increase
  • 13. Research and company-reported data suggest that pathways help standardize treatment and
  • save money in oncology
  • 14. Drivers and resistors to the use of oncology pathways from different stakeholder perspectives
  • 15. The place of pathways in the changing oncology payment landscape
  • 16. Bibliography

ONCOLOGY PATHWAYS AND PHARMA

  • 17. Remember that the pathway's first step is in the clinical development program
  • 18. Oncology pathway inclusion will increasingly hinge on available biomarkers
  • 19. Open the transparency dialog with third-party pathway vendors
  • 20. Off-pathway and "ahead-of-pathway" messaging can drive success at the margins
  • 21. Recognize that oncology pathways could be protective for novel, high-priced therapies
  • 22. Bibliography

FUTURE OF ONCOLOGY PATHWAYS

  • 23. Fragmentation or consolidation: the jury is still out
  • 24. The limited role of patients could be expanding
  • 25. Oncology medical societies will help drive pathways to progress in the private and potentially
  • the public sector
  • 26. Pathways will enter public sector payment models as components of larger APMs
  • 27. "Big data" in medicine: help or harm for pathways?
  • 28. Bibliography
Back to Top